title: Impact of intensive treatment on serum methylglyoxal levels among individuals with screen-detected type 2 diabetes: the ADDITION-Denmark study.
abstract: OBJECTIVE
  Methylglyoxal (MG) has been implicated in the development of micro- and macrovascular diabetic complications, but it remains unclear how current treatments of type 2 diabetes affect its circulating levels.
  
  
  METHODS
  In the Danish arm of the ADDITION trial, we (a) described serum MG levels at baseline and at 6-year follow-up among individuals with screen-detected type 2 diabetes, (b) examined the effect of intensive multifactorial treatment compared with routine care on MG, (c) examined the associations between MG and risk factors at baseline and at follow-up and (d) examined the associations between changes in MG and changes in risk factors.
  
  
  RESULTS
  Patients in both treatment arms experienced a significant decline in MG from baseline to follow-up, with no effect of allocation to intensive treatment. In cohort analyses, MG was associated with smoking and fasting glucose at baseline and smoking and LDL cholesterol at follow-up. Compared with patients receiving no lipid-lowering treatment, patients receiving lipid-lowering treatment had higher MG at follow-up, and those initiating lipid-lowering treatment experienced a less pronounced decline in MG.
  
  
  CONCLUSIONS
  Further studies are required to explore any possible effects of the observed decrease in MG in type 2 diabetes patients as well as the potential interplay between MG, lipids, lipid-lowering treatment and smoking.
authors: Steno Diabetes Center, NSK 2.11, Niels Steensens Vej 1, 2820, Gentofte, Denmark. TMYJ@steno.dk.
authors: Troels M
authors: TM
authors: Jensen
authors: Steno Diabetes Center, NSK 2.11, Niels Steensens Vej 1, 2820, Gentofte, Denmark.
authors: Dorte
authors: D
authors: Vistisen
authors: Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
authors: Thomas
authors: T
authors: Fleming
authors: Department of Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
authors: Peter P
authors: PP
authors: Nawroth
authors: Steno Diabetes Center, NSK 2.11, Niels Steensens Vej 1, 2820, Gentofte, Denmark.
authors: Marit E
authors: ME
authors: Jørgensen
authors: Department of Public Health, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark.
authors: Torsten
authors: T
authors: Lauritzen
authors: Department of Public Health, Faculty of Health Sciences, Aarhus University, Aarhus, Denmark.
authors: Annelli
authors: A
authors: Sandbæk
authors: Department of Public Health, Aarhus University, Aarhus, Denmark.|Danish Diabetes Academy, Odense, Denmark.
authors: Daniel R
authors: DR
authors: Witte
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D008078:Cholesterol, LDL / Q000097:blood; D015331:Cohort Studies; D003718:Denmark; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011765:Pyruvaldehyde / Q000097:blood*; D012307:Risk Factors; D012907:Smoking / Q000097:blood
chemical_list: D001786:Blood Glucose; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D011765:Pyruvaldehyde
keywords: ADDITION-Denmark; Clinical; Complications; Methylglyoxal